Machine learning meets molecular depth AI and multi-omics for translational research

The future of translational research and the most exciting advances are happening at the intersection of AI, multi-omics, biomarker development, and biospecimen strategy, each essential for capturing the biological variability that shapes precision medicine. This panel brings together scientists, technologists, and strategists driving the next generation of biomarker & diagnostic discovery and validation. You’ll hear from leaders at Precision for Medicine, SOPHiA GENETICS, and Olink, part of Thermo Fisher; partners at the forefront of multi-omics integration, AI-powered analytics, genomics and high-plex proteomics as they discuss leading-edge practices and where the field is headed in 2026.

Key Discussion Topics:

Integrating Innovation: How SOPHiA GENETICS and Olink are pushing the boundaries of data interpretability, genomics, and proteomics for translational research.
Connecting Specimen to Signal: Precision for Medicine’s biospecimen experts will share how integrated sample collection and processing workflows ensure high-quality inputs for multi-omic assays and AI-driven analysis, enabling reproducible insights while accounting for biological diversity across diverse patient populations
AI-Driven Biomarker Development: How multi-omic data and machine learning are accelerating the connection between discovery biology and clinical endpoints through coordinated assay design
On the horizon for 2026: Explore how AI and multi-omics are shaping adaptive trial design, regulatory strategy, and the evolution of companion diagnostics.

Who Should Attend:

Built for biotech, pharma, and diagnostic researchers who are shaping the next generation of precision medicine:

Translational & biomarker discovery scientists
Computational biologists, AI/ML teams, and bioinformaticians
Clinical development & companion diagnostic leaders
R&D strategy and precision medicine program owners

Speakers:

Deb Phippard Chief Scientific Officer, Precision for Medicine
Philippe Menu EVP, Chief Medical Officer & Chief Product Officer, SOPHiA GENETICS
Heng (Tony) Qian Head of Data Science (North America), Olink, part of Thermo Fisher Scientific
Rob Fannon Head of Biospecimen Solutions, Precision for Medicine

Watch Webinar

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Institution(Required)

Job Title(Required)

Area of Interest(Required)

Email(Required)

Phone(Required)

Country(Required)

Select US State

Privacy Policy(Required)

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Marketing Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

This field is hidden when viewing the form

Job Title/Industry(Required)

CAPTCHA

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are those of the speakers and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services